



ADVITECH ANNOUNCES STOCK OPTION GRANTS

TSX VENTURE EXCHANGE: AVI

FOR IMMEDIATE RELEASE

QUEBEC – September 6, 2006 - Advitech Inc. (TSX-V: AVI) announces that pursuant to the Company's stock option plan, it has granted a total of 560,000 stock options to its employees and a consultant. These options have an exercise price of \$0.15 per share and are valid for a period of five (5) years.

This grant of options is subject to regulatory approval.

About Advitech

Advitech is a biotechnology Company specializing in the development of bioactive ingredients from dairy proteins. Its key focus areas are in the fields of immunology and inflammation. Its main platform, XP-828L, is a growth factor complex aimed at treating psoriasis, inflammatory bowel diseases and other chronic immune-mediated inflammatory diseases (IMID). Advitech's common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of outstanding common shares is 54,799,818.

-30-

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Advitech inc.

Renaud Beauchesne, MBA
President and Chief Executive Officer
(418) 686-7498, ext. 228
r.beauchesne@advitech.com
www.advitech.com